{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T21:53:30Z","timestamp":1793224410836,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.intimp.2024.111827","type":"journal-article","created":{"date-parts":[[2024,3,10]],"date-time":"2024-03-10T08:46:13Z","timestamp":1710060373000},"page":"111827","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["The role of BAFF and BAFF-R inhibitors in the treatment of immune thrombocytopenia; a focused review"],"prefix":"10.1016","volume":"131","author":[{"given":"Mohammad Ali","family":"Nilforoushzadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazila","family":"Heidari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Heidari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yekta","family":"Ghane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Lotfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fariba","family":"Jaffary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minou","family":"Najar Nobari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niloufar","family":"Najar Nobari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.intimp.2024.111827_b0005","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/MOH.0000000000000612","article-title":"An update on the pathophysiology of immune thrombocytopenia","volume":"27","author":"Semple","year":"2020","journal-title":"Curr. Opin. Hematol."},{"issue":"1","key":"10.1016\/j.intimp.2024.111827_b0010","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12959-023-00509-z","article-title":"Risk of thrombotic events in immune thrombocytopenia patients treated with thrombopoietic agents: a systematic review and meta-analysis","volume":"21","author":"Dong","year":"2023","journal-title":"Thromb. J."},{"issue":"4","key":"10.1016\/j.intimp.2024.111827_b0015","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/ejh.12777","article-title":"Thromboembolism in adults with primary immune thrombocytopenia: a systematic literature review and meta-analysis","volume":"97","author":"Doobaree","year":"2016","journal-title":"Eur. J. Haematol."},{"issue":"1","key":"10.1016\/j.intimp.2024.111827_b0020","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000449038","article-title":"Is autoimmune thrombocytopenia itself the primary disease in the presence of second diseases data from a long-term observation","volume":"44","author":"Aboud","year":"2017","journal-title":"Transfus Med. Hemother."},{"key":"10.1016\/j.intimp.2024.111827_b0025","doi-asserted-by":"crossref","first-page":"613192","DOI":"10.3389\/fmed.2021.613192","article-title":"Understanding immune thrombocytopenia: looking out of the box","volume":"8","author":"Schifferli","year":"2021","journal-title":"Front. Med. (lausanne)"},{"issue":"22","key":"10.1016\/j.intimp.2024.111827_b0030","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","article-title":"Updated international consensus report on the investigation and management of primary immune thrombocytopenia","volume":"3","author":"Provan","year":"2019","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.intimp.2024.111827_b0035","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.3324\/haematol.2020.259481","article-title":"Efficacy, safety and immunological profile of combining rituximab with belimumab for adults with persistent or chronic immune thrombocytopenia: results from a prospective phase 2b trial","volume":"106","author":"Mah\u00e9vas","year":"2021","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.intimp.2024.111827_b0040","first-page":"3876","article-title":"BAFF level increased in patients with autoimmune hemolytic anemia","volume":"8","author":"Zhao","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"10.1016\/j.intimp.2024.111827_b0045","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1053\/j.seminhematol.2013.03.021","article-title":"Immune Thrombocytopenia and B-Cell-Activating Factor\/A Proliferation-Inducing Ligand","volume":"50","author":"Liu","year":"2013","journal-title":"Semin. Hematol."},{"issue":"14","key":"10.1016\/j.intimp.2024.111827_b0050","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1182\/blood-2017-06-789578","article-title":"BAFF and CD4(+) T cells are major survival factors for long-lived splenic plasma cells in a B-cell-depletion context","volume":"131","author":"Thai","year":"2018","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.intimp.2024.111827_b0055","first-page":"2053","article-title":"B-cell activating factor receptor expression is associated with germinal center B-cell maintenance","volume":"17","author":"Carrillo-Ballesteros","year":"2019","journal-title":"Exp Ther Med"},{"issue":"2","key":"10.1016\/j.intimp.2024.111827_b0060","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1586\/1744666X.2015.996550","article-title":"Belimumab for the treatment of systemic lupus erythematosus","volume":"11","author":"Jordan","year":"2015","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"10.1016\/j.intimp.2024.111827_b0065","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/nbt.2076","article-title":"The discovery and development of belimumab: the anti-BLyS-lupus connection","volume":"30","author":"Stohl","year":"2012","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.intimp.2024.111827_b0070","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.3389\/fimmu.2018.02698","article-title":"Inhibition of Membrane-Bound BAFF by the Anti-BAFF Antibody Belimumab","volume":"9","author":"Kowalczyk-Quintas","year":"2018","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.intimp.2024.111827_b0075","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1080\/03009742.2023.2247881","article-title":"Belimumab therapy for refractory immune thrombocytopenia in systemic lupus erythematosus patients with anti-phospholipid antibodies","volume":"53","author":"Dong","year":"2024","journal-title":"Scand J Rheumatol"},{"issue":"5","key":"10.1016\/j.intimp.2024.111827_b0080","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.smim.2006.04.006","article-title":"APRIL and their receptors: structure, function and signaling","volume":"18","author":"Bossen","year":"2006","journal-title":"Semin Immunol"},{"issue":"8","key":"10.1016\/j.intimp.2024.111827_b0085","doi-asserted-by":"crossref","first-page":"4570","DOI":"10.4049\/jimmunol.1001708","article-title":"BAFF receptor signaling aids the differentiation of immature B cells into transitional B cells following tonic BCR signaling","volume":"185","author":"Rowland","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.intimp.2024.111827_b0090","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.coi.2021.05.011","article-title":"BAFF signaling in B cell metabolism","volume":"71","author":"McAllister","year":"2021","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.intimp.2024.111827_b0095","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.coi.2021.06.014","article-title":"BAFF signaling in health and disease","volume":"71","author":"Schweighoffer","year":"2021","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.intimp.2024.111827_b0100","doi-asserted-by":"crossref","first-page":"111435","DOI":"10.1016\/j.intimp.2023.111435","article-title":"A systematic review of Janus kinase inhibitors and spleen tyrosine kinase inhibitors for Hidradenitis suppurativa treatment","volume":"127","author":"Heidari","year":"2024","journal-title":"Int Immunopharmacol"},{"issue":"7","key":"10.1016\/j.intimp.2024.111827_b0105","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.186.7.1027","article-title":"A critical role for Syk in signal transduction and phagocytosis mediated by Fcgamma receptors on macrophages","volume":"186","author":"Crowley","year":"1997","journal-title":"J Exp Med"},{"issue":"Supplement 1","key":"10.1016\/j.intimp.2024.111827_b0110","doi-asserted-by":"crossref","first-page":"8408","DOI":"10.1182\/blood-2022-158236","article-title":"Efficacy and Safety of Tyrosine Kinase Inhibitors in the Treatment of Relapsed\/Refractory Immune Thrombocytopenia","volume":"140","author":"Ali","year":"2022","journal-title":"Blood"},{"issue":"3\u20134","key":"10.1016\/j.intimp.2024.111827_b0115","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.cytogfr.2008.04.006","article-title":"TACI, an enigmatic BAFF\/APRIL receptor, with new unappreciated biochemical and biological properties","volume":"19","author":"Mackay","year":"2008","journal-title":"Cytokine Growth Factor Rev"},{"issue":"3","key":"10.1016\/j.intimp.2024.111827_b0120","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/jth.13246","article-title":"Participation of B-cell-activating factor receptors in the pathogenesis of immune thrombocytopenia","volume":"14","author":"Min","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"20","key":"10.1016\/j.intimp.2024.111827_b0125","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1182\/bloodadvances.2020003860","article-title":"Abnormalities of bone marrow B cells and plasma cells in primary immune thrombocytopenia","volume":"5","author":"Yu","year":"2021","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.intimp.2024.111827_b0130","doi-asserted-by":"crossref","first-page":"7276","DOI":"10.4049\/jimmunol.179.11.7276","article-title":"Regulated expression of BAFF-binding receptors during human B cell differentiation","volume":"179","author":"Darce","year":"2007","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.intimp.2024.111827_b0135","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","article-title":"B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches","volume":"34","author":"Shah","year":"2020","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.intimp.2024.111827_b0140","doi-asserted-by":"crossref","first-page":"131","DOI":"10.18773\/austprescr.2016.053","article-title":"Rituximab in autoimmune diseases","volume":"39","author":"Randall","year":"2016","journal-title":"Aust Prescr"},{"issue":"7","key":"10.1016\/j.intimp.2024.111827_b0145","doi-asserted-by":"crossref","first-page":"e1399","DOI":"10.1002\/cti2.1399","article-title":"Neutrophils contribute to elevated BAFF levels to modulate adaptive immunity in patients with primary immune thrombocytopenia by CD62P and PSGL1 interaction","volume":"11","author":"Xu","year":"2022","journal-title":"Clin Transl Immunology"},{"issue":"1","key":"10.1016\/j.intimp.2024.111827_b0150","doi-asserted-by":"crossref","first-page":"2131751","DOI":"10.1080\/09537104.2022.2131751","article-title":"Recent advances in understanding spleen tyrosine kinase (SYK) in human biology and disease, with a focus on fostamatinib","volume":"34","author":"Cooper","year":"2023","journal-title":"Platelets"},{"issue":"12","key":"10.1016\/j.intimp.2024.111827_b0155","doi-asserted-by":"crossref","first-page":"e22912","DOI":"10.1016\/j.heliyon.2023.e22912","article-title":"Efficacy and safety of Bruton's tyrosine kinase inhibitors in the treatment of pemphigus: A comprehensive literature review and future perspective","volume":"9","author":"Ghane","year":"2023","journal-title":"Heliyon"},{"issue":"5","key":"10.1016\/j.intimp.2024.111827_b0160","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10051004","article-title":"Emerging Therapies in Immune Thrombocytopenia","volume":"10","author":"Audia","year":"2021","journal-title":"J Clin Med"},{"issue":"3","key":"10.1016\/j.intimp.2024.111827_b0165","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.immuni.2012.11.015","article-title":"The BAFF receptor transduces survival signals by co-opting the B cell receptor signaling pathway","volume":"38","author":"Schweighoffer","year":"2013","journal-title":"Immunity"},{"issue":"15","key":"10.1016\/j.intimp.2024.111827_b0170","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1056\/NEJMoa2110297","article-title":"Rilzabrutinib, an Oral BTK Inhibitor, Immune Thrombocytopenia","volume":"386","author":"Kuter","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.intimp.2024.111827_b0175","first-page":"e25887","article-title":"The Role of Belimumab in Systemic Lupus Erythematosis: A Systematic Review","volume":"14","author":"Joy","year":"2022","journal-title":"Cureus"},{"issue":"6","key":"10.1016\/j.intimp.2024.111827_b0180","first-page":"1056","article-title":"Efficacy of belimumab for the long-term maintenance therapy of thrombocytopenia in systemic lupus erythematosus","volume":"35","author":"De Marchi","year":"2017","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.intimp.2024.111827_b0185","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/mrcr\/rxad055","article-title":"Successful treatment with belimumab for immune thrombocytopenia associated with systemic lupus erythematosus: A report of two cases","volume":"8","author":"Nakayama","year":"2023","journal-title":"Mod Rheumatol Case Rep"},{"key":"10.1016\/j.intimp.2024.111827_b0190","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.cytogfr.2021.11.004","article-title":"B cell-activating factor and its targeted therapy in autoimmune diseases","volume":"64","author":"Zhang","year":"2022","journal-title":"Cytokine Growth Factor Rev."},{"issue":"10320","key":"10.1016\/j.intimp.2024.111827_b0195","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0140-6736(21)02251-0","article-title":"Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sj\u00f6gren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial","volume":"399","author":"Bowman","year":"2022","journal-title":"Lancet"},{"issue":"Supplement 1","key":"10.1016\/j.intimp.2024.111827_b0200","doi-asserted-by":"crossref","first-page":"5427","DOI":"10.1182\/blood-2023-180055","volume":"142","author":"Cuker","year":"2023","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.intimp.2024.111827_b0205","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1136\/annrheumdis-2018-214720","article-title":"Treatment of primary Sj\u00f6gren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity","volume":"78","author":"D\u00f6rner","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2024.111827_b0210","unstructured":"A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies, 2023. https:\/\/clinicaltrials.gov\/study\/NCT05885555?intr=Ianalumab&rank=2."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692400345X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692400345X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T06:43:38Z","timestamp":1731739418000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156757692400345X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":42,"alternative-id":["S156757692400345X"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.111827","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of BAFF and BAFF-R inhibitors in the treatment of immune thrombocytopenia; a focused review","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.111827","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"111827"}}